All In Biotech

Drug Trial Radar · NCT07282509

Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer

A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of Transcatheter Arterial Infusion of Paclitaxel Cationic Liposome Combined With Systemic Therapy in Participants With Advanced Hepatocellular Carcinoma for Second-line Treatment

Last checked: Nov 19, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 116 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

116

Planned (sponsor's estimate)

Start

Dec 23, 2025

Primary completion

Jun 26, 2028

Study completion Feb 3, 2029

Sponsor

Sponsor type
Industry
First posted
Dec 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is an open-label, dose-escalation, and randomized controlled Phase Ib/II clinical study for second-line treatment in participants with advanced hepatocellular carcinoma (HCC). Its primary objective is to evaluate the safety, tolerability, pharmacokinetic profiles, and efficacy of transcatheter arterial infusion of HA131 combined with systemic therapy in the second-line treatment of participants with advanced HCC.

Conditions

  • Advanced Hepatocellular Carcinoma (HCC)

Interventions

  • HA131Drug

    Phase Ib: Dose escalation. Phase II: Administration at the RP2D dose determined in Phase Ib. Transcatheter Arterial Infusion.

  • Enlonstobart InjectionDrug

    Administered via intravenous infusion.

  • Pembrolizumab InjectionDrug

    Administered via intravenous infusion.

  • Lenvatinib Mesilate CapsulesDrug

    Administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib-DLTTime frame: 3years
  2. Phase Ib- AETime frame: 3years
  3. Phase II- ORRTime frame: 3years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.